Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from OrbusNeich Medical Group Holdings Limited ( (HK:6929) ) is now available.
OrbusNeich Medical Group Holdings has proposed a final ordinary cash dividend of HKD 0.12 per share for the financial year ended 31 December 2025, underscoring its intention to return capital to shareholders. The distribution, subject to shareholder approval on 8 June 2026, will be paid in Hong Kong dollars without withholding tax implications, with an ex‑dividend date of 10 June, a record date of 16 June and payment scheduled for 26 June 2026.
The timetable sets a clear window for investors, including a book closure period from 12 to 16 June 2026 to determine dividend entitlements. The move signals management’s confidence in the group’s financial performance and may enhance the stock’s appeal to income‑focused investors, reinforcing OrbusNeich’s positioning as a returning‑cash, yield‑oriented healthcare play in the Hong Kong market.
The most recent analyst rating on (HK:6929) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on OrbusNeich Medical Group Holdings Limited stock, see the HK:6929 Stock Forecast page.
More about OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited is a Hong Kong‑listed medical company focused on interventional medical devices. The group operates in the healthcare sector, providing products and services related to cardiovascular and other minimally invasive treatments, targeting hospitals, physicians and healthcare providers in its core markets.
Average Trading Volume: 103,040
Technical Sentiment Signal: Sell
Current Market Cap: HK$3B
For a thorough assessment of 6929 stock, go to TipRanks’ Stock Analysis page.